December 2007
PharmaWatch: CNS;Dec2007, Vol. 6 Issue 12, p14
Market Research Report
The article profiles UCB, a global biopharmaceutical company engaged in the research, development and commercialization of pharmaceutical and biotechnology products. It is said that in the epilepsy therapeutic category, the company markets brands such as Keppra and Nootropil. Moreover, for treatment of allergy, it offers Xyzal and Zyrtec brands. Further discussion about its products and the development of its company is presented.


Related Articles

  • Biopharm turns to plastic. Aldridge, Susan // Pharmaceutical Technology Europe;Mar2007, Vol. 19 Issue 3, p22 

    Many biotech drugs are now being made in single-use disposable reactors, with big gains in process flexibility, and cuts in cleaning time and costs. As suppliers develop an ever-widening range of plastic components, manufacturers are fast learning to do without steel piping and fermenters.

  • Biotech, generics provide fuel for U.S. Rx growth in '06. Chater, Amanda // Drug Store News;3/20/2006, Vol. 28 Issue 4, p17 

    The article reports that the U.S. pharmaceutical market has improved in 2005 and is predicted to grow from 5 percent to 8 percent over the next five years. This was revealed in a repot from IMS Health. Prescription drug sales increased by 5.4 percent in 2005 to $251.8 billion. Biotechnology...

  • Research & Markets: The Essential 2011 Global Pharmaceuticals Industry Guide With Profiles of the Leading Companies in the Industry.  // Biomedical Market Newsletter;5/14/2011, p216 

    The article focuses on the "Global: Pharmaceuticals Industry Guide," which contains the profiles of the leading companies in the industry. The reports provides expert analysis with distinct chapters for generics, life sciences tools & services, pharmaceuticals, biotechnology and life sciences....

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.

  • Epilepsy Update.  // PharmaWatch: CNS;Mar2006, Vol. 5 Issue 3, p6 

    The article reports on developments about drugs for treating epilepsy. The U.S. Food and Drug Administration has requested more information before approving the intravenous version of UCB SA's Keppra drug. Keppra was also recommended for approval by an advisory committee to the European...

  • New realities force Rx makers to adapt. Ubl, Stephen // Chain Drug Review;1/4/2016, Vol. 38 Issue 1, p103 

    The article discusses the GBI Research's report on the challenges facing pharmaceutical and biotechnology companies due to disruptive events in the health care market. Topics discussed include the strategies that companies are considering to overcome the challenges, drug development to treat...

  • UCB clinches deal for biopharma big league slot. Beacham, Will // European Chemical News;5/24/2004, Vol. 80 Issue 2101, p9 

    Announces that Belgian chemicals and pharmaceuticals group UCB has agreed a cash bid for British biotechnology company Celltech in May 2004. Value of the bid; Overview of the drug license deal between the companies; Significance of the move to Celltech; Background of Celltech.

  • UCB: Strong Future for Peptide-Based Therapies. Scott, Alex // Chemical Week;12/11/2002, Vol. 164 Issue 48, p27 

    Presents information on the prediction of Braine-l' Alleud, Belgium-based UCB-Bioproducts regarding the sales growth of peptide-based active pharmaceutical ingredients. Applications of peptide-based therapies; Reason behind the growth of peptide-based therapies.

  • FURTHER READING.  // PharmaWatch: Biotechnology;Mar2005, Vol. 4 Issue 3, p26 

    A list of latest reports and briefs related to the biotechnology industries is presented including "Stakeholder Opinions: Non-Hodgkin's Lymphoma: Immunotherapy Stimulates the Market," "Market Leaders in Oncology 2004: Roche and Genentech Continue to Blaze a Trail," and "Vaccine Manufacturing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics